PDS Biotechnology to unveil new PDS0301 clinical outcomes at upcoming expert event

PDS Biotechnology to unveil new PDS0301 clinical outcomes at upcoming expert event
PDS Biotech unveils trial data

PDS Biotechnology announced it will host a virtual key opinion leader (KOL) event on October 15 at 8 a.m. ET. The event will feature Dr. Jonathan M. Hernandez of the U.S. National Cancer Institute, who will join company management to discuss phase 2 clinical outcomes for PDS0301 in advanced liver-associated cancers, with a focus on metastatic colorectal cancer (mCRC).

This session aims to provide an update on the progress of PDS Biotechnology's ongoing research and development in cancer therapeutics.

PDS Biotechnology recently published Phase 2 trial results for its HPV16 immunotherapy and announced a shift in focus to PDS0301 in metastatic colorectal cancer (mCRC). The company is continuing its research in cancer therapeutics with ongoing clinical programs. The upcoming KOL event follows these recent milestones in its development strategy.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.